X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17274) 17274
Newsletter (2808) 2808
Book Review (1599) 1599
Publication (1127) 1127
Newspaper Article (139) 139
Magazine Article (83) 83
Conference Proceeding (54) 54
Book Chapter (28) 28
Dissertation (9) 9
Book / eBook (5) 5
Reference (5) 5
Trade Publication Article (4) 4
Transcript (2) 2
Data Set (1) 1
Presentation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (13554) 13554
niacinamide (10142) 10142
humans (8211) 8211
animals (6623) 6623
niacinamide - analogs & derivatives (6141) 6141
male (5365) 5365
female (3889) 3889
niacinamide - pharmacology (3560) 3560
research (2627) 2627
rats (2616) 2616
middle aged (2306) 2306
niacinamide - therapeutic use (2275) 2275
analysis (2236) 2236
mice (2219) 2219
oncology (2133) 2133
sorafenib (2001) 2001
cancer (1960) 1960
phosphates (1908) 1908
aged (1838) 1838
phenylurea compounds (1808) 1808
adult (1768) 1768
biochemistry & molecular biology (1722) 1722
antineoplastic agents - therapeutic use (1634) 1634
enzymes (1613) 1613
purines (1608) 1608
physiological aspects (1581) 1581
pharmacology & pharmacy (1544) 1544
nicotinamide (1534) 1534
niacinamide - administration & dosage (1425) 1425
treatment outcome (1288) 1288
liver neoplasms - drug therapy (1196) 1196
carcinoma, hepatocellular - drug therapy (1152) 1152
phenylurea compounds - therapeutic use (1128) 1128
oxidative stress (1111) 1111
reports (1096) 1096
niacinamide - metabolism (1087) 1087
apoptosis (1055) 1055
nad (1047) 1047
cell line, tumor (1024) 1024
pyridines - therapeutic use (1009) 1009
benzenesulfonates - therapeutic use (966) 966
care and treatment (932) 932
oxidases (931) 931
cell biology (879) 879
expression (874) 874
time factors (858) 858
dose-response relationship, drug (801) 801
niacin (795) 795
nad - metabolism (779) 779
antineoplastic agents (775) 775
liver neoplasms - pathology (774) 774
hepatocellular carcinoma (765) 765
metabolism (759) 759
proteins (752) 752
antineoplastic agents - pharmacology (748) 748
kinetics (748) 748
old medline (746) 746
abridged index medicus (741) 741
carcinoma, hepatocellular - pathology (734) 734
antimitotic agents (733) 733
carcinoma, renal cell - drug therapy (733) 733
kidney neoplasms - drug therapy (722) 722
article (719) 719
health aspects (709) 709
antineoplastic agents - adverse effects (702) 702
universities and colleges (700) 700
protein kinase inhibitors - therapeutic use (699) 699
niacinamide - adverse effects (694) 694
cells (687) 687
phenylurea compounds - administration & dosage (686) 686
adenine (671) 671
phenylurea compounds - pharmacology (671) 671
niacinamide - chemistry (666) 666
aged, 80 and over (660) 660
neurosciences (643) 643
apoptosis - drug effects (642) 642
glucose (639) 639
cells, cultured (620) 620
liver (620) 620
superoxide (615) 615
in vitro techniques (612) 612
nitric oxide (606) 606
medical research (590) 590
pyridines - pharmacology (584) 584
activation (582) 582
coenzymes (573) 573
therapy (565) 565
antioxidants (563) 563
gene expression (561) 561
nicorandil (550) 550
chemotherapy (549) 549
drug therapy (548) 548
rats, wistar (543) 543
cell proliferation - drug effects (539) 539
liver cancer (539) 539
biophysics (530) 530
endocrinology & metabolism (529) 529
tumors (529) 529
survival (527) 527
angiogenesis (525) 525
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18529) 18529
Russian (580) 580
German (296) 296
Italian (241) 241
French (197) 197
Japanese (153) 153
Chinese (119) 119
Ukrainian (51) 51
Polish (41) 41
Spanish (41) 41
Czech (15) 15
Hungarian (12) 12
Portuguese (11) 11
Dutch (9) 9
Romanian (7) 7
Korean (6) 6
Turkish (6) 6
Bulgarian (5) 5
Danish (5) 5
Swedish (5) 5
Norwegian (3) 3
Afrikaans (2) 2
Slovak (2) 2
Armenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cell Metabolism, ISSN 1550-4131, 10/2016, Volume 24, Issue 4, p. 526
In this issue, Fang et al. (2016) show that both the DNA repair defect and mitochondrial dysfunction in ATM.sup.-/- cells or mice are mitigated by the... 
Niacinamide
Journal Article
Food Chemistry, ISSN 0308-8146, 12/2013, Volume 141, Issue 3, p. 3207
acents pH.sub.24h, nitrifyers and muscle types affected nutritional attributes of dry-cured ham. acents Oxidative status of dry-cured ham was related to... 
Niacinamide
Journal Article
Equine Veterinary Journal, ISSN 0425-1644, 06/2014, Volume 46, Issue S46, pp. 27 - 27
There are no published studies that characterize the different myofiber types of Mangalarga (ML) horses and hybrids. This study aimed to characterize and... 
Niacinamide
Journal Article
Cell Biochemistry & Function, ISSN 0263-6484, 10/2014, Volume 32, Issue 7, p. 557
  Alzheimer's disease (AD) is the most common form of dementia and is characterized by the presence of senile plaques and neurofibrillary tangles, along with... 
Niacinamide
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 11/2010, Volume 20, Issue 22, p. 6812
Journal Article
Journal Article
Cell Metabolism, ISSN 1550-4131, 08/2016, Volume 24, Issue 2, pp. 269 - 282
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3794 - 3801
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2015, Volume 33, Issue 2, pp. 172 - 179
Purpose This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma... 
ANGIOGENESIS | ONCOLOGY | PATHWAY | SUNITINIB | ABT-869 | RISK | BRIVANIB | INHIBITOR | CANCER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - etiology | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Odds Ratio | Drug Administration Schedule | Risk Factors | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Niacinamide - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Sorafenib | Carcinoma, Hepatocellular - pathology | Aged | Indazoles - adverse effects | Indazoles - therapeutic use | Index Medicus | Bone3 | ORIGINAL REPORTS | Bios3
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1344 - 1354
Summary Background There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy... 
Hematology, Oncology and Palliative Medicine | CLINICAL-PRACTICE GUIDELINES | DIAGNOSIS | LIVER-TRANSPLANTATION | RISK-FACTORS | THERAPY | MANAGEMENT | ONCOLOGY | SAFETY | PREVENTION | RECURRENCE | Catheter Ablation - mortality | South America | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Hepatectomy - mortality | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | North America | Young Adult | Carcinoma, Hepatocellular - drug therapy | Time Factors | Aged, 80 and over | Liver Neoplasms - pathology | Catheter Ablation - adverse effects | Chemotherapy, Adjuvant | Europe | Risk Factors | Niacinamide - adverse effects | Niacinamide - therapeutic use | Disease Progression | New Zealand | Protein Kinase Inhibitors - administration & dosage | Intention to Treat Analysis | Niacinamide - analogs & derivatives | Liver Neoplasms - mortality | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Double-Blind Method | Hepatectomy - adverse effects | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Neoplasm Recurrence, Local | Phenylurea Compounds - therapeutic use | Carcinoma, Hepatocellular - surgery | Liver Neoplasms - surgery | Treatment Outcome | Niacinamide - administration & dosage | Disease-Free Survival | Phenylurea Compounds - administration & dosage | Asia | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Australia | Antimitotic agents | Liver cancer | Medical colleges | Surgery | Liver | Clinical trials | Hepatoma | Antineoplastic agents | Index Medicus
Journal Article
by Vilgrain, Valérie and Pereira, Helena and Assenat, Eric and Guiu, Boris and Ilonca, Alina Diana and Ilonca, Alina D and Pageaux, Georges-Philippe and Sibert, Annie and Bouattour, Mohamed and Lebtahi, Rachida and Allaham, Wassim and Barraud, Hélène and Laurent, Valérie and Mathias, Elodie and Bronowicki, Jean-Pierre and Tasu, Jean-Pierre and Perdrisot, Rémy and Silvain, Christine and Gerolami, René and Mundler, Olivier and Seitz, Jean-Francois and Vidal, Vincent and Aubé, Christophe and Oberti, Frédéric and Couturier, Olivier and Brenot-Rossi, Isabelle and Raoul, Jean-Luc and Sarran, Anthony and Costentin, Charlotte and Itti, Emmanuel and Luciani, Alain and Adam, René and Lewin, Maïté and Samuel, Didier and Ronot, Maxime and Dinut, Aurelia and Castera, Laurent and Chatellier, Gilles and Delhom - Christol, Elisabeth and Lonjon, Julie and Abdel-Rehim, Mohamed and Dieudonné, Arnaud and Bazin, Christophe and Chagneau-Derrode, Carine and Borentain, Patrick and Bouvier, Antoine and Vervueren, Laurent and Chalaye, Julia and Kobeiter, Hicham and Edeline, Julien and Garin, Etienne and Rolland, Yan and Archambeaud, Isabelle and Eugene, Thomas and Frampas, Eric and Cassinotto, Christophe and Guyot, Martine and Hiriart, Jean-Baptiste and Lapuyade, Bruno and Vergniol, Julien and Bachellier, Philippe and Detour, Julien and Duclos, Bernard and Greget, Michel and Habersetzer, Francois and Imperiale, Alessio and Merle, Philippe and Rode, Agnès and Morvan, Julie and Nguyen-Khac, Eric and Yzet, Thierry and Baudin, Guillaume and Chevallier, Patrick and Mahamat, Abakar and Piche, Thierry and Razzouk, Micheline and Hillon, Patrick and Loffroy, Romaric and Toubeau, Michel and Vincent, Julie and Barabino, Gabriele and Bouarioua, Nadia and Cuilleron, Muriel and Ecochard, Marie and Prevot-Bitot, Nathalie and Leroy, Vincent and Roux, Julie and Sengel, Christian and Bourcier, Valérie and Ganne-Carrie, Nathalie and Seror, Olivier and Costo, Sylvie and Dao, Thông and Pelage, Jean-Pierre and Dumortier, Jérôme and Giammarile, Francesco and Valette, Pierre-Jean and Ghazzar, Nadia and Pellerin, Olivier and Taieb, Julien and ... and SARAH Trial Grp and SARAH Trial Group
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1624 - 1636
Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of... 
SURVIVAL | THERAPY | ONCOLOGY | COMPETING RISK | TRANSARTERIAL CHEMOEMBOLIZATION | RADIOEMBOLIZATION | QUALITY-OF-LIFE | Niacinamide - analogs & derivatives | Carcinoma, Hepatocellular - mortality | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Liver Neoplasms - mortality | Dose-Response Relationship, Drug | Microspheres | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Neoplasm Invasiveness - pathology | Phenylurea Compounds - adverse effects | Adult | Female | Liver Neoplasms - pathology | Yttrium Radioisotopes - therapeutic use | Radiotherapy Dosage | Drug Administration Schedule | Administration, Oral | Brachytherapy - methods | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Carcinoma, Hepatocellular - radiotherapy | Treatment Outcome | Niacinamide - administration & dosage | Disease-Free Survival | Phenylurea Compounds - administration & dosage | Liver Neoplasms - radiotherapy | Sorafenib | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Neoplasm Staging | Rare earth metals | Antimitotic agents | Product development | Hepatoma | Comparative analysis | Radiotherapy | Antineoplastic agents | Index Medicus | Life Sciences | Liver Neoplasms/drug therapy | Phenylurea Compounds/administration & dosage | Yttrium Radioisotopes/therapeutic use | Niacinamide/analogs & derivatives | Carcinoma, Hepatocellular/radiotherapy | Carcinoma, Hepatocellular/drug therapy | Cancer
Journal Article
Journal of Comparative Pathology, ISSN 0021-9975, 01/2017, Volume 156, Issue 1, pp. 141 - 141
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9940, pp. 319 - 328
Journal Article